ODAC Resumes After Nine-Month Gap With AstraZeneca NDA Review

AstraZeneca faces a pivotal advisory committee review as the FDA's Oncologic Drugs Advisory Committee convenes April 29 to evaluate two AstraZeneca applications, including an NDA for camizestrant in combination with a CDK4/6 inhibitor for HR+HER2- breast cancer. For regulatory affairs teams, the committee's posture on this submission will set observable precedent for how ODAC frames benefit-risk assessments in the HR+HER2- space and what CMC expectations accompany combination regimen NDAs going forward.

The meeting marks ODAC's first convening after a hiatus of more than nine months, a gap that has left oncology regulatory teams with limited recent committee guidance to benchmark against. The return of structured advisory activity matters operationally: ODAC recommendations, while non-binding, consistently shape FDA's final review calculus and signal the evidentiary thresholds reviewers are applying to efficacy and safety packages in oncology submissions.

What regulatory teams should track:

• How ODAC frames the benefit-risk profile for camizestrant in combination with a CDK4/6 inhibitor will indicate the committee's current tolerance for surrogate endpoints in HR+HER2- breast cancer indications.
• The committee's questions to AstraZeneca may surface expectations around labeling, patient selection criteria, and post-marketing commitments that inform parallel submissions in the same therapeutic area.
• Any CMC-related discussion during open sessions could signal evolving FDA expectations for combination product manufacturing controls under 21 CFR Part 211 and ICH Q10 quality system frameworks.

Source reporting is drawn from Pharmaceutical Industry News, published April 29, 2026. The source article is limited in clinical and procedural detail; this report reflects only claims directly supported by the available source material.